- ￥720 - 1190
- AntibodySystem
- France
- FHE03410
- 2025年07月15日
- FCM
- Mouse
- Human
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 亚型：
IgG1, lambda
- 形态：
Liquid
- 保存条件：
-20 to -80°C
- 克隆性：
单克隆
- 标记物：
Unconjugated
- 适应物种：
Human
- 保质期：
twelve months
- 级别：
流式抗体
- 供应商：
武汉益普生物科技有限公司
- 宿主：
Mouse
- 应用范围：
FCM
- 抗体英文名：
Anti-Human CD80/B7-1 Antibody (IDEC-114)
- 抗体名：
CD80/B7-1抗体
- 规格：
50μg/100μg
| 规格： | 50μg | 产品价格： | ￥720.0 |
|---|---|---|---|
| 规格： | 100μg | 产品价格： | ￥1190.0 |
| 产品名 | Anti-Human CD80/B7-1 Antibody (IDEC-114) |
| 货号 | FHE03410 |
| 靶标 | CD80, BB1, T-lymphocyte activation antigen CD80, CD28LG, B7, CD28LG1, LAB7, Activation B7-1 antigen, CTLA-4 counter-receptor B7.1 |
| 克隆号 | IDEC-114 |
| 克隆类型 | Monoclonal |
| 同种型 | IgG1, lambda |
| 宿主 | Mouse |
| 种属反应性 | Human |
| 应用 | FCM |
| 偶联物 | Unconjugated |
| 内毒素水平 | Please contact with the lab for this information. |
| 纯度 | >95% as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS, pH 7.4. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| Note | For research use only. |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
Immunohistochemistry using Anti-Ganglioside Antibodies
, T., Terashima,T., and Tai, T.(1993) Generation of a monoclonal antibody specific for ganglioside GM4: evidence for GM4 expression on astrocytes in chicken cerebellum. J. Biochem.(Tokyo), 114 :5-8 3) Kotani, M., Kawashima, I., Ozawa, H., Ogura
双特异抗体(Bispecific antibody)的简介和制作方法
throughgrafting of complementarity determining regions (CDRs) or using various technologies for recovery of fully human antibodies, such as phage display libraries or transgenic mice expressing human antibody repertoires. Reduced immunogenicity of antibodies
技术资料暂无技术资料 索取技术资料
